Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Daiichi Sankyo Co Ltd Receives FDA Approval for Iron Deficiency Anemia Agent- Nikkan Kogyo


Monday, 5 Aug 2013 08:00pm EDT 

Nikkan Kogyo reported that Daiichi Sankyo Co Ltd has received U.S. Food and Drug Administration (FDA) approval for Injectafer, which is a parenteral iron replacement product used for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had an unsatisfactory response to oral iron. Injectafer is also indicated for iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease (NND-CKD).